Your browser is no longer supported. Please, upgrade your browser.
Settings
KIN [NASD]
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own0.40% Shs Outstand39.31M Perf Week-1.40%
Market Cap196.41M Forward P/E- EPS next Y-0.78 Insider Trans-29.01% Shs Float37.02M Perf Month20.54%
Income-26.60M PEG- EPS next Q-0.29 Inst Own67.90% Short Float2.05% Perf Quarter22.33%
Sales42.60M P/S4.61 EPS this Y0.90% Inst Trans0.58% Short Ratio3.39 Perf Half Y22.33%
Book/sh1.95 P/B2.53 EPS next Y-32.80% ROA-24.90% Target Price- Perf Year-48.96%
Cash/sh1.56 P/C3.15 EPS next 5Y40.00% ROE-34.80% 52W Range3.11 - 11.93 Perf YTD14.39%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-61.80% 52W High-58.68% Beta1.21
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin97.80% 52W Low58.78% ATR0.33
Employees156 Current Ratio12.70 Sales Q/Q-9.10% Oper. Margin-58.90% RSI (14)58.32 Volatility9.19% 7.42%
OptionableYes Debt/Eq0.25 EPS Q/Q21.10% Profit Margin-62.50% Rel Volume5.75 Prev Close4.45
ShortableYes LT Debt/Eq0.25 EarningsNov 09 AMC Payout- Avg Volume224.13K Price4.93
Recom2.00 SMA205.55% SMA5017.58% SMA20015.11% Volume1,289,598 Change10.79%
Mar-17-20Downgrade Guggenheim Buy → Neutral
Nov-13-19Reiterated H.C. Wainwright Buy $17.50 → $16
Jul-16-19Downgrade B. Riley FBR Buy → Neutral $18 → $8.50
Jun-11-19Initiated Barclays Overweight $13
May-23-19Initiated Stifel Buy
May-23-19Initiated Guggenheim Buy $11
Mar-07-19Reiterated Lake Street Buy $30 → $12
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
Dec-27-20 03:05AM  
Dec-22-20 08:31AM  
Dec-21-20 08:31AM  
Dec-11-20 06:49PM  
08:00AM  
Dec-02-20 04:02PM  
Nov-12-20 07:15AM  
Nov-11-20 08:32AM  
Nov-09-20 06:25PM  
04:02PM  
02:30PM  
Nov-02-20 12:31PM  
Oct-28-20 04:05PM  
Oct-08-20 11:37AM  
Oct-07-20 04:24PM  
08:02AM  
08:00AM  
Oct-06-20 12:50PM  
08:48AM  
Sep-28-20 09:28AM  
Sep-16-20 02:57PM  
08:03AM  
Sep-09-20 08:02AM  
Aug-31-20 05:00PM  
Aug-27-20 03:30PM  
Aug-05-20 06:25PM  
09:00AM  
Jul-29-20 12:33PM  
Jul-28-20 02:58PM  
Jul-23-20 08:32AM  
Jul-16-20 11:00AM  
Jul-08-20 12:00PM  
Jun-29-20 08:51AM  
Jun-19-20 04:30AM  
Jun-14-20 09:47PM  
Jun-08-20 04:02PM  
Jun-03-20 09:53AM  
May-24-20 10:34PM  
May-20-20 07:58AM  
May-13-20 08:30AM  
May-10-20 10:53AM  
May-09-20 11:01PM  
May-07-20 04:02PM  
May-02-20 10:00AM  
Apr-30-20 12:33PM  
Apr-23-20 08:32AM  
Apr-15-20 04:02PM  
Apr-14-20 05:02PM  
Mar-24-20 08:31AM  
Mar-18-20 06:53AM  
Mar-16-20 05:15PM  
04:02PM  
02:30PM  
08:18AM  
Mar-09-20 12:30PM  
Mar-03-20 04:02PM  
Feb-26-20 12:30PM  
Feb-18-20 08:30AM  
Feb-04-20 09:03AM  
Jan-08-20 04:02PM  
Jan-07-20 01:43AM  
Dec-23-19 07:31PM  
Dec-16-19 08:02AM  
Dec-12-19 09:05AM  
Dec-06-19 10:36AM  
Nov-28-19 02:29PM  
Nov-25-19 04:03PM  
Nov-14-19 04:05PM  
Nov-12-19 05:45PM  
04:01PM  
Nov-05-19 10:33AM  
Oct-28-19 08:31AM  
Oct-18-19 10:23AM  
Oct-10-19 04:02PM  
Oct-07-19 03:27PM  
Oct-02-19 07:01AM  
Sep-27-19 02:54AM  
Sep-10-19 07:01AM  
Aug-28-19 08:31AM  
Aug-07-19 10:51AM  
03:33AM  
Aug-02-19 10:24AM  
Aug-01-19 06:45PM  
04:01PM  
Jul-29-19 07:01AM  
Jul-16-19 08:31AM  
Jun-28-19 06:40PM  
Jun-21-19 09:47AM  
May-13-19 08:31AM  
May-10-19 01:24PM  
01:50AM  
May-09-19 06:15PM  
05:07PM  
04:01PM  
May-07-19 11:54AM  
Apr-25-19 08:01AM  
Mar-13-19 02:03AM  
Mar-07-19 01:19PM  
Mar-06-19 09:21PM  
04:01PM  
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bevers DeniseDirectorJan 14Option Exercise0.3213,0234,16713,023Jan 15 06:27 PM
Bevers DeniseDirectorJan 14Sale5.0013,02365,1150Jan 15 06:27 PM
Bevers DeniseDirectorJan 07Option Exercise0.3239,06912,50239,069Jan 08 07:03 PM
Bevers DeniseDirectorJan 07Sale5.0039,069195,3490Jan 08 07:03 PM
Bevers DeniseDirectorOct 07Option Exercise0.3212,5084,00312,508Oct 08 09:11 PM
Bevers DeniseDirectorOct 07Sale5.0112,50862,6280Oct 08 09:11 PM
Bevers DeniseDirectorSep 22Option Exercise0.32515165515Sep 24 06:45 PM
Bevers DeniseDirectorSep 22Sale5.005152,5750Sep 24 06:45 PM
Park West Asset Management LLC10% OwnerJun 26Sale4.71115,136542,2916,628,757Jun 30 09:30 PM